US Patent

US12233069 — Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor

Formulation · Assigned to BeiGene Switzerland GmbH · Expires 2040-06-10 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an oral solid tablet formulation of a Bruton's Tyrosine Kinase inhibitor and its preparation method.

USPTO Abstract

Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administration, quick and high-efficient release, no particular requirements on equipment, and a simple formulation preparation process, can ensure formulation stability and facilitate transportation and storage, and is suitable for large-scale production.

Drugs covered by this patent

Patent Metadata

Patent number
US12233069
Jurisdiction
US
Classification
Formulation
Expires
2040-06-10
Drug substance claim
No
Drug product claim
Yes
Assignee
BeiGene Switzerland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.